Aptose Biosciences enters US$8.5M loan agreement with Hanmi Pharmaceutical

On June 20, 2025, Aptose Biosciences Inc. (“Aptose”) announced that it had entered into a loan agreement (the “Loan Agreement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”). The Loan Agreement provides for an uncommitted facility of up to US$8.5 million, to be administered through multiple advances, for the purpose of supporting the continued clinical development of tuspetinib (TUS) in triplet therapy for acute myeloid leukemia.

The Loan Agreement constitutes a related-party transaction within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions, as Hanmi is a related party of Aptose under Canadian securities laws. Aptose is relying on the financial hardship exemption from the formal valuation and minority shareholder approval requirements under MI 61-101.

Aptose, headquartered in Toronto, Ontario, is a Canadian clinical-stage biotechnology company focused on developing oncology therapies, with an initial focus on hematology.

Hanmi Pharmaceutical, headquartered in Seoul, South Korea, is a global biopharmaceutical company specializing in oncology, diabetes, obesity, and metabolic diseases.

McCarthy Tétrault LLP advised Aptose with a team led by Charles-Antoine Soulière that included Michel Ranger, Kayla Ellison, Rhea Evans, Yassine Khadir (Business Law), and Jamey Gage (Bankruptcy & Restructuring).